Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 5/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 1.00 |
| ▸ | RGS12 | O14924 | 3/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 3/20 | 1.00 |
| ▸ | THPO | P40225 | 3/20 | 1.00 |
| ▸ | MTOR | P42345 | 3/20 | 1.00 |
| ▸ | GNAI1 | P63096 | 3/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 3/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 1.00 |
| ▸ | TP53 | P04637 | 2/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 2/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.98 |
| ▸ | LMNA | P02545 | 4/20 | 0.98 |
| ▸ | HPGD | P15428 | 4/20 | 0.98 |
| ▸ | PMP22 | Q01453 | 4/20 | 0.98 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.98 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1325960 | 1.00 | MAPT (1.00) | MAPTMAPK1ALDH1A1RGS12CYP1A2 | |
| SCHEMBL29380552 | 1.00 | MAPT (1.00) | MAPTMAPK1ALDH1A1RGS12CYP1A2 | |
| Bromide SCHEMBL1325232 | 0.99 | MAPT (1.00) | MAPTMAPK1ALDH1A1RGS12CYP1A2 | |
| Bromide SCHEMBL1325230 | 0.99 | MAPT (1.00) | MAPTMAPK1ALDH1A1RGS12CYP1A2 | |
| SCHEMBL10955950 | 0.92 | MAPT (0.85) | MAPTMAPK1ALDH1A1RGS12CYP1A2 | |
| SCHEMBL12878037 | 0.90 | DRD1 (1.00) | MAPTMAPK1ALDH1A1RGS12CYP1A2 | |
| SCHEMBL12284387 | 0.89 | DRD3 (1.00) | MAPTMAPK1ALDH1A1RGS12CYP1A2 | |
| SCHEMBL14535819 | 0.89 | DRD3 (1.00) | MAPTMAPK1ALDH1A1RGS12CYP1A2 | |
| SCHEMBL29387586 | 0.87 | DRD3 (1.00) | MAPTMAPK1ALDH1A1RGS12CYP1A2 | |
| SCHEMBL12284193 | 0.87 | DRD3 (1.00) | MAPTMAPK1ALDH1A1RGS12CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030162231-A1 | Alzheimer's disease; antiagglomerant of amyloid deposits | TENNESSEE RESEARCH FOUNDATION, UNIVERSITY | 2003-08-28 | — | — | US | claimed |
| EP-0040074-B1 | N-SUBSTITUTED APORPHINES, A METHOD OF INDUCING EMESIS AND A METHOD OF CONTROLLING PSYCHOSIS UTILISING THE SAME | NORTHEASTERN UNIVERSITY (US) | 1985-07-31 | — | — | EP | claimed |
| EP-0040074-A1 | N-substituted aporphines, a method of inducing emesis and a method of controlling psychosis utilising the same | NORTHEASTERN UNIVERSITY (US) | 1981-11-18 | — | — | EP | claimed |
| WO-2018162522-A1 | USE OF DOPAMINE RECEPTOR AGONIST FOR THE TREATMENT OF A COLORECTAL CANCERS | UNIVERSITY OF COPENHAGEN (DK) | 2018-09-13 | — | — | WO | disclosed |
| US-8058243-B2 | Method for treating a brain cancer with ifenprodil | HSC RESEARCH AND DEVELOPMENT LIMITED PARTNERSHIP (CA) | 2011-11-15 | — | — | US | disclosed |
| US-20110218158-A1 | DNA CYTOSINE DEAMINASE INHIBITORS | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2011-09-08 | — | — | US | disclosed |
| US-20110218158-A1 | DNA CYTOSINE DEAMINASE INHIBITORS | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2011-09-08 | — | — | US | disclosed |
| US-20100168085-A1 | Dopamine and agonists and antagonists thereof for modulation of suppressive activity of CD4+CD25+ regulatory T cells | YESA RESEARCH AND DEVELOPMENT CO. LTD. AT THE WEIZMANN INSTITUTE OF SCIENCE (IL) | 2010-07-01 | — | — | US | disclosed |
| WO-2010033986-A2 | DNA CYTOSINE DEAMINASE INHIBITORS | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2010-03-25 | — | — | WO | disclosed |
| US-20060234385-A1 | Polyglutamine repeat sequences | WETZEL RONALD | 2006-10-19 | — | — | US | disclosed |
| US-7067321-B2 | Polyglutamine repeat sequences | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2006-06-27 | — | — | US | disclosed |
| EP-1626703-A2 | DOPAMINE AND AGONISTS AND ANTAGONISTS THEREOF FOR MODULATION OF SUPPRESSIVE ACTIVITY OF CD4+CD25+ REGULATORY T CELLS | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2006-02-22 | — | — | EP | disclosed |
| WO-2004103262-A2 | DOPAMINE AND AGONISTS AND ANTAGONISTS THEREOF FOR MODULATION OF SUPPRESSIVE ACTIVITY OF CD4+CD25+ REGULATORY T CELLS | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2004-12-02 | — | — | WO | disclosed |
| US-20030162231-A1 | Alzheimer's disease; antiagglomerant of amyloid deposits | TENNESSEE RESEARCH FOUNDATION, UNIVERSITY | 2003-08-28 | — | — | US | disclosed |
| EP-0040074-B1 | N-SUBSTITUTED APORPHINES, A METHOD OF INDUCING EMESIS AND A METHOD OF CONTROLLING PSYCHOSIS UTILISING THE SAME | NORTHEASTERN UNIVERSITY (US) | 1985-07-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110218158-A1 | DNA CYTOSINE DEAMINASE INHIBITORS | DCTD, APOBEC3A, UNG | MAPT 4260/4885MAPK1 4366/4885ALDH1A1 795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.